Phase 3 Trial Success for EuCorVac-19

[{ "selector": ".xqnbf-a", "duration": "500ms", "fill": "forwards", "delay": "950ms", "keyframes": [ {"offset": 0, "opacity": 0}, {"offset": 1, "opacity": "1"} ] }, { "selector": ".npmwb-a", "duration": "500ms", "fill": "forwards", "delay": "1250ms", "keyframes": [ {"offset": 0, "transform": "translateY(calc(600px - 502px))", "opacity": "1"}, {"offset": 1, "transform": "translateY(0)", "opacity": "1"} ] }]

Buffalo-based (POP BIO) reports Phase 3 interim results of EuCorVac-19 trial. Developed with Korean partner EuBiologics (KOSDAQ: 206650) [{ "selector": ".nmjbl-a", "duration": "500ms", "fill": "forwards", "delay": "1000ms", "keyframes": [ {"offset": 0, "opacity": 0}, {"offset": 1, "opacity": "1"} ] }]

EuCorVac-19

EuCorVac-19 is a Protein-based vaccine with antigen on immunogenic nanoparticles, using POP BIO's SNAP technology. [{ "selector": ".wedua-a", "duration": "500ms", "fill": "forwards", "delay": "750ms", "keyframes": [ {"offset": 0, "transform": "translateX(-330px) scale(0.15)", "opacity": "1"}, {"offset": 1, "transform": "translateX(0) scale(1)", "opacity": "1"} ] }, { "selector": ".ecrsx-a", "duration": "500ms", "fill": "forwards", "delay": "500ms", "keyframes": [ {"offset": 0, "transform": "translateX(-320px) scale(0.15)", "opacity": "1"}, {"offset": 1, "transform": "translateX(0) scale(1)", "opacity": "1"} ] }, { "selector": ".wopmi-a", "duration": "500ms", "fill": "forwards", "delay": "1000ms", "keyframes": [ {"offset": 0, "opacity": 0}, {"offset": 1, "opacity": "1"} ] }, { "selector": ".oulcm-a", "duration": "500ms", "fill": "forwards", "delay": "1250ms", "keyframes": [ {"offset": 0, "opacity": 0}, {"offset": 1, "opacity": "1"} ] }]

Phase 3 trial (NCT05572879) in the Philippines: EuCorVac-19 surpasses WHO-authorized adenoviral vector vaccine in antibody immunogenicity [{ "selector": ".gjqdx-a", "duration": "500ms", "fill": "forwards", "delay": "750ms", "keyframes": [ {"offset": 0, "transform": "translateX(-330px) scale(0.15)", "opacity": "1"}, {"offset": 1, "transform": "translateX(0) scale(1)", "opacity": "1"} ] }, { "selector": ".lnnwp-a", "duration": "500ms", "fill": "forwards", "delay": "1000ms", "keyframes": [ {"offset": 0, "transform": "translateX(-320px) scale(0.15)", "opacity": "1"}, {"offset": 1, "transform": "translateX(0) scale(1)", "opacity": "1"} ] }, { "selector": ".ulmjz-a", "duration": "500ms", "fill": "forwards", "delay": "1500ms", "keyframes": [ {"offset": 0, "opacity": 0}, {"offset": 1, "opacity": "90%"} ] }]

EuCorVac-19 exhibits over twofold increase in neutralizing antibody formation compared to control vaccine, preventing COVID-19 infection. [{ "selector": ".ggbzn-a", "duration": "500ms", "fill": "forwards", "delay": "1250ms", "keyframes": [ {"offset": 0, "opacity": 0}, {"offset": 1, "opacity": "90%"} ] }]

Future development of COVID-19 booster, new strain, and combination vaccines will be easier, streamlining progress [{ "selector": ".gswjp-a", "duration": "500ms", "fill": "forwards", "delay": "750ms", "keyframes": [ {"offset": 0, "transform": "translateY(calc(600px - 335px))", "opacity": "1"}, {"offset": 1, "transform": "translateY(0)", "opacity": "1"} ] }, { "selector": ".dizme-a", "duration": "500ms", "fill": "forwards", "delay": "1000ms", "keyframes": [ {"offset": 0, "transform": "translateY(calc(600px - 340px))", "opacity": "1"}, {"offset": 1, "transform": "translateY(0)", "opacity": "1"} ] }, { "selector": ".pgakt-a", "duration": "500ms", "fill": "forwards", "delay": "1250ms", "keyframes": [ {"offset": 0, "opacity": 0}, {"offset": 1, "opacity": "90%"} ] }]

"Completion of Phase III trial is a significant milestone for our technologies, validating our efforts to combat the global crisis," said POP BIO co-founder. [{ "selector": ".qnwiq-a", "duration": "500ms", "fill": "forwards", "delay": "1250ms", "keyframes": [ {"offset": 0, "opacity": 0}, {"offset": 1, "opacity": "90%"} ] }] Read More

Phase 3 Trial Success for EuCorVac-19

Courtesy: newsobserver.com

EuCorVac-19